Clemons NJ, Wang DH, Croagh D, Tikoo A, Fennell CM, Murone C, Scott AM, Watkins DN, Phillips WA. Sox9 drives columnar differentiation of esophageal squamous epithelium: a possible role in the pathogenesis of Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol 303: G1335-G1346, 2012. First published October 11, 2012 doi:10.1152/ajpgi.00291.2012.-The molecular mechanism underlying the development of Barrett's esophagus (BE), the precursor to esophageal adenocarcinoma, remains unknown. Our previous work implicated sonic hedgehog (Shh) signaling as a possible driver of BE and suggested that bone morphogenetic protein 4 (Bmp4) and Sox9 were downstream mediators. We have utilized a novel in vivo tissue reconstitution model to investigate the relative roles of Bmp4 and Sox9 in driving metaplasia. Epithelia reconstituted from squamous epithelial cells or empty vector-transduced cells had a stratified squamous phenotype, reminiscent of normal esophagus. Expression of Bmp4 in the stromal compartment activated signaling in the epithelium but did not alter the squamous phenotype. In contrast, expression of Sox9 in squamous epithelial cells induced formation of columnar-like epithelium with expression of the columnar differentiation marker cytokeratin 8 and the intestinal-specific glycoprotein A33. In patient tissue, A33 protein was expressed specifically in BE, but not in normal esophagus. Expression of Cdx2, another putative driver of BE, alone had no effect on reconstitution of a squamous epithelium. Furthermore, epithelium coexpressing Cdx2 and Sox9 had a phenotype similar to epithelium expressing Sox9 alone. Our results demonstrate that Sox9 is sufficient to drive columnar differentiation of squamous epithelium and expression of an intestinal differentiation marker, reminiscent of BE. These data suggest that Shh-mediated expression of Sox9 may be an important early event in the development of BE and that the potential for inhibitors of the hedgehog pathway to be used in the treatment of BE and/or esophageal adenocarcinoma could be tested in the near future.
BARRETT'S ESOPHAGUS (BE), a squamous to columnar metaplasia of the distal esophagus, often with intestinal features, is an established precursor and risk factor for the development of esophageal adenocarcinoma (EAC) (33) . Within Westernized nations, the dramatic increase in the incidence of EAC in the past few decades (6) is at least partly attributable to a concomitant increase in BE (5, 46) . Although the rate at which BE progresses to EAC is a matter of debate (9) , the rise in the incidence of BE should nevertheless be considered to represent a potential future increase in the number of patients likely to develop EAC. However, it is not possible to predict which patients with BE are likely to progress, nor are there treatments that convincingly prevent progression of BE or reverse metaplasia. Importantly, prognosis for patients with EAC is poor, with the majority of newly diagnosed patients surviving Ͻ1 yr after diagnosis (34) and an overall survival rate that ranks among the lowest of all adult cancers. As with other cancers, patient outcomes can be significantly improved if the disease is detected and treated at an early stage (24) . Therefore, increasing our understanding of the biology underlying the development of BE, the early precursor stage of EAC, is likely to enable improvements in the clinical management of patients with this condition.
While reflux is a well-established driver of BE (33) , the underlying molecular events, and therefore possible targets for therapeutic intervention or potential biomarkers, are largely unclear. The ultimate drivers of Barrett's metaplasia are likely to be transcription factors, which alter the differentiation of stem cells in the normal esophageal epithelium or promote transdifferentiation of squamous epithelial cells (17, 38) . Determining the key transcription factors driving BE pathogenesis will allow identification of upstream signaling pathways, which may be amenable to therapeutic targeting.
A number of candidate transcription factors that may be involved in the development of BE have been identified by combining gene expression profile comparisons of BE and normal esophagus with a priori knowledge of factors important in the development of the normal intestinal epithelium. These include the caudal-related homeobox genes CDX1 and CDX2, hepatocyte nuclear factors, GATA4, GATA6, and Hath1 (4) . In particular, experimental data suggesting a role for CDX1 and CDX2 in BE pathogenesis (16, 20, 26, 27, 49) have also been implicated in gastric intestinal metaplasia (31, 32, 37) . However, transgenic expression of CDX2 in the squamous epithelium of mice failed to induce columnar metaplasia or expression of columnar or intestinal differentiation markers (22) , suggesting that CDX2 alone may not be sufficient to drive BE.
Recently, we identified the transcription factor Sox9, downstream of the sonic hedgehog (Shh) signaling pathway, as a potential driver of BE (48) . The Sox transcription factors are known to be important in controlling cell fate and differentiation in embryonic development and the maintenance of adult tissues (3, 19, 30, 41, 42) . Sox9 has essential roles in the development of cartilage, testes, neural crest, and spinal cord glial cells (2, 12, 21, 39, 41, 47). In the intestine, Sox9 is expressed in the crypts, where it is regulated by the Wnt pathway (27, 34) . Although not a specific marker, Sox9 is expressed by intestinal crypt stem cells (11) and has recently been shown to mark a zone of progenitor cells in the liver and pancreas, in addition to the intestine (13) . Knockout of Sox9 results in a lack of Paneth and goblet cell differentiation (27, 34) .
Our previous study showed that Sox9, which is a known downstream target of Shh signaling in chondrocytes (44) , is expressed in the basal epithelial cells of the developing mouse esophagus from embryonic day 12.5 until birth but is not expressed in the adult mouse esophageal epithelium (48) . This pattern of expression is consistent with Sox9 being downstream of Shh signaling, which is known to be essential for the development of the embryonic columnar-lined esophagus but is switched off in the adult esophagus (25, 35) . Furthermore, our data showed that Sox9 is universally upregulated in BE and frequently expressed in EAC but is absent in normal human squamous esophagus (48) . Using an in vivo tissue reconstitution model, we demonstrated that ectopic Shh expression could induce expression of the columnar differentiation in mouse esophageal squamous epithelium (MES), which correlated with expression of Sox9 in the epithelium and bone morphogenetic protein 4 (Bmp4) in the underlying stroma (48) . Bmp4 was shown by others to induce expression of columnar markers in primary human squamous esophageal epithelial cells in vitro (28) , although the mechanism of action was not determined. However, neither our study (48) nor that of Milano et al. (28) reported evidence of intestinal differentiation, suggesting that additional factors are required to produce an epithelium more reminiscent of BE.
In the current study, we utilized our unique in vivo tissue reconstitution system to further investigate the role of Bmp4 and Sox9 as putative drivers of BE downstream of Shh. We aimed to determine whether 1) Bmp4 or Sox9 alone is sufficient to drive changes in esophageal squamous epithelium reminiscent of BE and 2) CDX2 could cooperate with Sox9 to further alter differentiation of squamous epithelium toward an intestinal-type columnar epithelium.
MATERIALS AND METHODS
Ethics. This project was approved by the Animal Experimentation Ethics Committee and the Human Ethics Committee of the Peter MacCallum Cancer Centre. Immunohistochemistry for A33 in human tissue samples was conducted under an approved protocol from the Austin Health Human Ethics Committee. All human tissue samples were obtained and used with the full written consent of the donors. All experimental procedures involving animals were conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes published by the National Health and Medical Research Council of Australia.
Primary cell isolation and culture. Primary MES cells from wild-type C57/B6 mice were isolated as previously described (7, 8) . The majority of cells isolated by this method stain for cytokeratin (Ck) 14 (Ck14), indicating their basal epithelial origin (43) . Freshly isolated cells were immediately used in the tissue reconstitution assay, cultured in EpiGro Keratinocyte Complete Medium (Millipore, Billerica, MA) to allow retroviral transduction, or incubated with 100 ng/ml mouse recombinant Bmp4 (rBmp4; R & D Systems, Minneapolis, MN). Primary human esophageal fibroblasts (HEFs) were isolated from normal esophageal squamous mucosa at the margins of surgical resection specimens. The squamous epithelium was removed following incubation in 6 mg/ml Dispase II (Roche Diagnostics, Mannheim, Germany) in PBS with 12 g/ml penicillin, 160 g/ml gentamicin, and 600 ng/ml fluconazole (PBS ϩϩϩ ), and fibroblasts were isolated from the remaining stromal component by further digestion in 4 mg/ml Dispase II and 3 mg/ml collagenase A (Roche) in PBS ϩϩϩ . Isolated stromal cells, consisting mostly of fibroblasts, were cultured in DMEM with 10% FCS.
Retroviral expression constructs. A full-length cDNA expression construct for mouse Bmp4 contained within the retroviral vector MSCV-IRES-Cherry was a kind gift of Dr. Bedrich Eckhardt (Peter MacCallum Cancer Centre). Human CDX2 cDNA expression construct was a kind gift of Dr. Michael Michael (Flinders University) and was subcloned into MSCV-IRES-GFP. The full-length coding cDNA sequence for mouse Sox9 was cloned by PCR amplification from embryonic mouse brain cDNA using specific primers [5=-GACCGAATTCATGAATCTCCTGGACCCCTT-3= (forward) and 5=-GATGCTCGAGTCAGGGTCTGGTGAGCTGTG-3= (reverse)] that introduced EcoRI and XhoI restriction sites (underlined) at the 5= and 3= ends of the leading strand, respectively, for direct cloning into MSCV-IRES-GFP. Sequence of the cDNA insert was confirmed by the Sanger method.
Retroviral transductions. Retroviral supernatants were created by transfection of Phoenix A packaging cells with 1 g of retroviral expression vector using Lipofectamine LTX [Invitrogen (currently Life Technologies), Grand Island, NY] according to the manufacturer's instructions. For transduction of human fibroblasts, retroviral supernatant from transfected Phoenix A cells was used to transduce PT67 amphotropic packaging cells. Freshly plated primary cultures of MES cells or HEFs were transduced on 3 consecutive days by incubation in retroviral supernatant with 8 g/ml Polybrene for 1 h each day. For Sox9 and CDX2 cotransduction, each retroviral supernatant was produced separately, and transductions were performed with a 1:1 mixture of both supernatants. Transduction efficiency in epithelial cells was qualitatively assessed by examination of green fluorescent protein (GFP) expression under a fluorescence microscope, and an efficiency of Ͼ30% was deemed suitable for transplantation into the in vivo tissue reconstitution assay. To maximize the exposure of epithelial cells to Bmp4 when cotransplanted with transduced fibroblasts, pure populations of Bmp4-expressing fibroblasts were isolated by fluorescence-activated cell sorting (FACS) for Cherry fluorescence. Fresh transductions were performed for each tissue reconstitution experiment.
In vivo tissue reconstitution assay. The in vivo tissue reconstitution assay was performed as previously described (7, 8) . Briefly, rat tracheas from Sprague-Dawley rats (Animal Resources Centre, Canning Vale, Australia), devitalized by three cycles of freeze-thawing (Ϫ80°C to 37°C), were inoculated with suspensions of wild-type MES cells (3 ϫ 10 5 -5 ϫ 10 5 /trachea) mixed with HEF-EV or HEF-Bmp4 cells (1 ϫ 10 5 -3 ϫ 10 5 /trachea, total cell number 6 ϫ 10 5 ) or transduced [Sox9, CDX2, Sox9 ϩ CDX2, or empty vector (EV) 3 ϫ 10 5 -5 ϫ 10 5 /trachea] MES cells only. Tracheas were sealed with LIGACLIPs and then implanted subcutaneously under the dorsal skin of 6-to 8-wk-old SCID mice while under general anesthesia from a ketamine-xylazil cocktail. After 3 or 6 wk, tracheas were harvested, fixed in 10% neutral buffered formalin, decalcified in 20% (wt/vol) EDTA in PBS, and embedded in paraffin. Transverse sections were cut for assessment of morphology (hematoxylin-eosin staining) and immunohistochemistry (IHC). Each experiment was performed in duplicate for each time point and repeated on two to three independent occasions.
Bmp4 ELISA. Bmp4, secreted in conditioned medium from FACS Bmp4-or EV-transduced fibroblasts, was detected with a DuoSet ELISA kit (R & D Systems) according to the manufacturer's instructions. Briefly, cells were plated at 2.5 ϫ 10 5 cells/well in six-well plates and allowed to adhere overnight; then the medium was replaced with serum-free DMEM, the cells were cultured for a further 24 h, and the conditioned medium was passed through filters with 0.22-m pore size. Aliquots of conditioned medium (100 l) were applied to the ELISA in triplicate, and the concentration was determined by measurement against a seven-point standard curve formed using twofold serial dilutions of rBmp4 with a maximum of 1,000 pg/ml. The ELISA was repeated on two independent occasions (n ϭ 3).
IHC. IHC was performed on paraffin sections following removal of paraffin with xylene and rehydration in a graded series of ethanol to water. Antigen retrieval was achieved by boiling sections at 125°C in a pressure cooker in 10 mM citrate (pH 6) or High pH Antigen Retrieval Buffer (Dako, Glostrup, Denmark). Sections were blocked in Dual Endogenous Enzyme Block (Dako) followed by 10% (wt/vol) BSA in Tris-buffered saline containing 0.05% Tween 20 (TBS-T) and incubated with primary antibodies (Table 1 ) diluted in 1% (wt/vol) BSA in TBS-T for 1 h at room temperature or overnight at 4°C. Primary antibodies were visualized using EnVisionϩ Detection System (Dako) according to the manufacturer's protocol, and sections were counterstained with hematoxylin. Three to six sections from different parts of the rat trachea were assessed for each antibody. IHC on positive and negative control tissues was performed concurrently with staining of rat trachea sections. IHC for A33 in human tissue [normal esophagus (n ϭ 3) and BE (n ϭ 5)] was performed on fresh frozen sections fixed in acetone for 10 min at 4°C and incubated with primary antibody for 30 min at room temperature, and primary antibody was visualized as described above.
Western blotting. Cells were harvested in RIPA lysis buffer [1% (vol/vol) NP-40, 1% (wt/vol) sodium deoxycholate, 0.1% (wt/vol) SDS, 150 mM NaCl, and 50 mM Tris, pH 8.0] containing phosphatase and protease inhibitor cocktails (PhosSTOP and complete Mini EDTA-free, respectively, Roche). Protein lysates (50 g total protein) were separated by electrophoresis on 10% polyacrylamide gels and transferred to polyvinylidene difluoride membranes. Membranes were blocked in 5% (wt/ vol) nonfat milk powder in TBS-T and probed with appropriate antibodies (Table 1 ) diluted in 1% (wt/vol) nonfat milk powder in TBS-T. Bound fluorescent-conjugated secondary antibodies were detected using an Odyssey infrared imaging system (LI-COR, Lincoln, NE).
SYBR Green quantitative real-time PCR. RNA was isolated from cells using TRIzol (Invitrogen) according to the manufacturer's instructions. cDNA was synthesized from total RNA with random hexamers (Promega, Madison, WI) using Transcriptor reverse transcriptase (Roche). Real-time PCR was performed in triplicate with specific primers for Sox9 [5=-GGG CGA GCA CTC TGG GCA AT-3= (forward) and 5=-CGT CGC GGA AGT CGA TGG GG-3= (reverse)], Bmp4 [5=-CGT CTT GGA GCC TGC AGC GA-3= (forward) and 5=-GCG TCG CTC CGA ATG GCA CT-3= (reverse)], and ␤-actin [5=-GAC GGC CAG GTC ATC ACT AT-3= (forward) and 5=-GTA CTT GCG CTC AGG AGG AG-3= (reverse)] at 200 nM each, using SYBR Green I Master (Roche) on a PCR machine (LightCycler 480, Roche). Expression of Bmp4 or Sox9 was calculated relative to ␤-actin in the same sample [⌬Cp ϭ Cp gene Ϫ Cp␤-actin (where Cp is the crossing point on the LightCycler)], and expression of Bmp4 in rBmp4-treated cells or Sox9 in MSCV-Sox9-IRES-GFP transduced cells was normalized to untreated or EVtransduced cells, respectively (⌬⌬Cp ϭ ⌬Cp test Ϫ ⌬Cpcontrol).
Sucrase-isomaltase reporter assay. HEK-293 cells were transiently transfected using FuGENE (Roche Diagnostics) with 0.5 g of a sucraseisomaltase luciferase reporter vector [pGL3-SI, described elsewhere (45) CA) with 0.5 g of MSCV-CDX2-IRES-eGFP or EV. Cells were harvested 48 h after transfection in Triton-Gly-Gly lysis buffer [1% (vol/vol) Triton X-100, 25 mM glycylglycine, 15 mM MgSO 4, 4 mM EGTA, and 1 mM DTT, pH 7.8] and analyzed for luciferase activity using a Fluostar OPTIMA luminometer (BMG Labtech, Ortenberg, Germany). Results were adjusted for transfection efficiency by determination of ␤-galactosidase activity in cell lysates. Five independent experiments were performed, each conducted in triplicate. ing Bmp4 derived from stromal fibroblasts (48). Here we have tested this hypothesis using an in vivo tissue reconstitution model. We expressed full-length mouse Bmp4 cDNA in primary HEFs isolated from normal esophageal tissue (Fig. 1) . Human fibroblasts were used, so that we could differentiate between transplanted fibroblasts and infiltrating host mouse fibroblasts in our in vivo model. Fibroblasts transduced with Bmp4 (HEF-Bmp4) or EV (HEF-EV) were sorted by FACS for Cherry fluorescence (coexpressed as a separate protein by the retroviral vector) (Fig. 1A) . The spindle-shaped appearance (Fig. 1B) and expression (Fig. 1C) of ␣-smooth muscle actin (␣-SMA) confirmed the fibroblast phenotype of the isolated cells. Expression of Bmp4 was confirmed by Western blotting (Fig. 1C) . HEF-Bmp4 cells, but not parental or HEF-EV cell lysates, showed a band at ϳ45 kDa, which corresponds to the unprocessed form of Bmp4, and a second band at ϳ20 kDa, which corresponds to the mature, active form of Bmp4 that is secreted from cells (Fig. 1C) . Secretion of Bmp4 from transduced HEFs was confirmed by ELISA (Fig. 1D) . Levels of Bmp4 in HEF-EV conditioned medium were minimal (Ͻ12 pg/ml) and were 20-fold higher in HEF-Bmp4 conditioned medium (243 pg/ml, P Ͻ 0.01; Fig. 1D ). We then used these cells to examine the effect of stromal Bmp4 on the reconstitution of an epithelium from primary wild-type (C57/B6) MES cells in our in vivo model. In this model, esophageal epithelial tissue is allowed to grow within a devitalized rat trachea transplanted under the dorsal skin of a SCID mouse (7, 8) . Epithelia were reconstituted over 3 or 6 wk from freshly isolated MES cells cotransplanted into rat tracheas with HEF-EV or HEF-Bmp4. Histopathological analysis of cross sections from control (MES ϩ HEF-EV) rat tracheas showed a normal-looking stratified squamous epithelium, with a polarized basal layer, suprabasal flayers, several layers of differentiated flattened squames, and keratinized layers, which are present in the mouse esophagus, but not in the human esophagus (Fig. 2) . Epithelia reconstituted for 3 wk in the presence of Bmp4 (MES ϩ HEF-Bmp4) had a basal layer that, in places, appeared columnar, with elongated nuclei orientated perpendicular to the basal layer (Fig. 2) . However, this phenotype was not consistent throughout the reconstituted epithelium and was not apparent at 6 wk (Fig. 2) . IHC confirmed the presence of Bmp4 in fibroblasts underlying the epithelium, as well as accumulation in some epithelial cells, but expression was absent in control epithelia (Fig. 2) . In serial sections, the presence of Bmp4 correlated with expression of phosphorylated Smad1/5/8 (pSmad1/5/8, an indicator of Bmp4 signaling pathway activation) in basal and occasional suprabasal cells of the epithelium (Fig. 2) . Expression of pSmad1/5/8 was predominantly nuclear, consistent with its translocation to the nucleus following activation. However, expression of Ck8 (Fig. 2 ) and a range of other columnar (Ck20), intestinal (Muc2, villin, A33, CDX2, and Alcian blue staining), and gastric (Muc5AC) epithelial markers in further serial sections was not detected in any of the reconstituted epithelia (data not shown). Furthermore, expression of the transcription factor Sox9 was not detected in serial sections of control or Bmp4-expressing tissue (Fig. 3) . Detection of a human-specific mitochondrial antigen confirmed the human origin of the fibroblasts underlying the epithelium in the control and Bmp4-containing reconstituted tissue (Fig. 3) . Similar results were obtained regardless of the MES-to-HEF ratio.
RESULTS

Bmp4 is not sufficient to induce columnar or intestinal differentiation of MES cells in vitro or in an in
Since Bmp4 protein was detected in some basal layer cells in the epithelium reconstituted in the presence of HEFBmp4 (Fig. 2) , we sought to determine whether Bmp4 could induce its own expression in MES cells. Compared with mouse embryonic brain tissue, MES cells express very low, but detectable, levels of Bmp4 mRNA, which was unaltered following treatment with mouse rBmp4 for 2, 6, or 24 h (Fig. 4A ). Bmp4 protein expression was undetectable in untreated MES cells, while cells treated with rBmp4 showed a band at ϳ17-20 kDa, which corresponds to the size of the active form of Bmp4 and is the same size as the rBmp4 (Fig.  4B) . Taken together, these results indicate that Bmp4 itself is not a downstream target of Bmp4 signaling in MES cells and that the Bmp4 detected in the reconstituted epithelium is likely to have originated from the HEF-Bmp4 cells.
Given that Bmp4 had been shown to induce expression of columnar markers in primary human squamous esophageal epithelial cells in vitro (28), we also examined the effect of rBmp4 on Ck8/18 expression in primary MES cells in vitro. Similar to the tissue reconstitution model, rBmp4 activated signaling in MES cells, as indicated by expression of pSmad1/ 5/8 (Fig. 4C) , but did not induce expression of the columnar marker Ck8/18 or Sox9 (Fig. 4D) . Taken together with the findings from the tissue reconstitution model, these results suggest that Bmp4 alone is not sufficient to induce columnar differentiation of MES cells, nor is it sufficient to induce expression of Sox9. 
MES-EV MES-Sox9
Sox9 is sufficient to drive formation of a columnar epithelium with expression of the intestinal marker A33 in an in vivo
tissue reconstitution model. Our previous study also implicated Sox9 as a factor downstream of Shh signaling that drives columnar differentiation in the development of BE (48) . Therefore, we next examined whether expression of Sox9 is sufficient to induce columnar differentiation in epithelium reconstituted from MES cells in our in vivo model. Freshly isolated MES cells were transduced in two-dimensional cultures with retrovirus containing full-length mouse Sox9 cDNA contained within the MSCV-IRES-GFP retroviral expression vector or with EV alone. Successful transduction was confirmed by detection of GFP using fluorescence microscopy ( Fig. 5A ) and FACS (data not shown). Cultures that exhibited Ͼ30% transduced cells were deemed suitable for use in the tissue reconstitution assays. Expression of Sox9 in bulk populations of transduced cells was determined by quantitative real-time PCR (Fig. 5B) . Expression of Sox9 mRNA was approximately sevenfold higher than in EV-transduced cells (P Ͻ 0.01).
Interestingly, immediately after transduction, even though the cultures contained a mixture of wild-type and transduced cells, there was a modest, but significant (1.7-fold, P Ͻ 0.02), upregulation of Ck8 mRNA and a trend toward increased Ck18 mRNA (2.8-fold, P ϭ 0.1) in Sox9-transduced cultures compared with EV-transduced cultures (Fig. 5B) .
Unsorted MES populations (i.e., containing a mixture of transduced and nontransduced cells) were then grown in the in vivo tissue reconstitution model for 3 or 6 wk (n ϭ 3 for each time point, in duplicate). Transplantation of unsorted cells allowed the comparison of wild-type MES cells with Sox9-expressing cells within the same rat trachea in addition to control rat tracheas containing EV-transduced MES cells. Expression of Sox9 promoted reconstitution of a columnar-like epithelium with evidence of intestinal differentiation (Figs. 6  and 7) . Patches of epithelium showing nuclear expression of Sox9, consistent with its role as a transcription factor, were only one to two layers thick, cuboidal or columnar in shape, demonstrated expression of the columnar marker Ck8, and lacked evidence of squamation or keratinization (Fig. 6, A and  B) . Expression of Ck8 was observed after 3 and 6 wk of growth, while the columnar-like morphology was more extensive at 6 wk. In contrast, adjacent wild-type epithelium and EV control epithelium, which were negative for Sox9, exhibited a normal, stratified squamous morphology and completely lacked Ck8 expression (Fig. 6, A and B ; EV control 6 wk data not shown). In some areas, expression of Sox9 also correlated with expression of the intestinal-specific glycoprotein A33, although its expression was more diffuse compared with in the predominantly membranous staining in mouse intestine (Fig.  7A) . None of the other columnar (Ck20), intestinal (villin, Muc2, CDX2, and Alcian blue staining), or gastric (Muc5AC) markers was detected (data not shown). A33 is expressed in normal human colon and BE, but not in normal human squamous esophagus (Fig. 7B) . These results show that Sox9 is sufficient to drive formation of a columnar epithelium that expresses columnar (Ck8) and intestinal (A33) markers from squamous esophageal epithelial cells.
CDX2 does not promote intestinal or columnar differentiation in mouse esophageal epithelial cells.
Given that CDX2 is proposed to be an important mediator of Barrett's metaplasia (16, 20, 26, 27, 49) and that ectopic expression of CDX2 can cause intestinal metaplasia in gastric columnar epithelial cells (31, 37), we hypothesized that coexpression of CDX2 and Sox9 might promote further intestinalization of the Sox9-driven columnar epithelium. We first examined the effect of ectopic CDX2 expression alone on MES cells grown in our tissue reconstitution model. Full-length human CDX2 cDNA contained within MSCV-IRES-GFP was introduced into freshly isolated MES cells via retroviral transduction, and expression was confirmed by Western blotting (Fig. 8A) . Unsorted populations of MES cells transduced with MSCV-CDX2-IRES-GFP (MES-CDX2) were transplanted into the rat trachea model (n Ͼ 3, in duplicate). Expression of CDX2 alone in MES did not alter the reconstitution of a stratified squamous epithelium after 3 or 6 wk of growth in the tissue reconstitution model (Fig. 8B) . Distinct nuclear staining for CDX2, consistent with its role as a transcription factor, could be detected in patches in basal and suprabasal squamous cell layers. Serial sections were negative for Ck8 and Sox9 (Fig. 8B) , as well as other columnar (Ck20), intestinal (A33, villin, Muc2, and Alcian blue staining), and gastric (Muc5AC) markers (data not shown). This suggests that CDX2 alone is not sufficient to induce columnar differentiation in MES cells. Functional activity of the CDX2 construct was confirmed by the ability to activate luciferase expression in a sucrase-isomaltase reporter construct following cotransfection of the reporter with CDX2 in HEK-293 cells (Fig. 8C) . We next simultaneously coinfected MES cells with CDX2-and Sox9-containing retroviruses and transplanted unsorted populations of cells into the tissue reconstitution model (n ϭ 3, in duplicate). Reconstituted epithelium demonstrated patches of cells expressing Sox9 and CDX2 in serial sections, indicating successful cotransduction of some MES cells (Fig. 9) . Patches of Sox9-or CDX2-only-expressing epithelium were also evident, indicating infection of cells with only one of the retroviruses, and these patches showed the same phenotype as the tissue reconstituted from MES cells transduced with the respective single retroviral construct ( Fig. 9 ; data not shown). The epithelium coexpressing Sox9 and CDX2 appeared similar to that observed when Sox9 only was expressed: it was only one to two cell layers thick, was more cuboidal or columnar in appearance, and correlated with expression of Ck8 in serial sections (Fig. 9) . Furthermore, coexpression of CDX2 with Sox9 failed to promote further columnar or intestinal differentiation, as determined by the lack of expression of our remaining panel of markers (Ck20, villin, Muc2, Alcian blue staining, and Muc5AC; data not shown).
DISCUSSION
Here we have shown for the first time that the transcription factor Sox9 is sufficient to drive columnar differentiation and expression of the intestinal-specific glycoprotein A33 in squamous esophageal epithelium. The phenotype of the Sox9-expressing epithelium in our unique in vivo model was clearly columnar or cuboidal and lacked the multilayering, squamation, and keratinization of wild-type and EV control reconstituted epithelium. This is in contrast to studies by others using in vitro three-dimensional cultures to study putative drivers of BE, in which cells within the cultured epithelium express columnar or intestinal markers, yet the overall epithelium retains a squamous morphology (23, 40) . We previously showed that Sox9 is expressed in most, if not all, cases of BE (48) . Increased Sox9 expression has also been described in intestinal metaplasia in the stomach (36) . Our findings presented here provide mechanistic evidence that is consistent with Sox9 having an important role in the development of BE. We previously demonstrated activation of the Shh pathway in BE and proposed a paracrine mechanism with Sox9 expression being driven by Bmp4 from stromal cells (48) . We have modeled this hypothesis using a unique in vivo tissue reconstitution model and demonstrate that although Bmp4 derived from stromal cells was able to activate signaling in mouse squamous esophageal epithelial cells, it was not sufficient to induce columnar differentiation. Similarly, treatment of MES cells with mouse rBmp4 in vitro also did not induce columnar differentiation.
Interestingly, we did not see any evidence of Sox9 expression in response to Bmp4 in our in vivo model or in vitro in MES cells. This may reflect a difference in downstream signaling targets of Bmp4 between mice and humans, since Bmp4 signaling can induce Sox9 and Ck8/18 expression in the human squamous esophageal epithelial cell line HET-1A (48) . Consistent with this idea, a previous study reported that rBmp4 can induce expression of columnar cytokeratins in primary human esophageal squamous epithelial cells in vitro (28) , although expression of Sox9 was not determined in that study.
We previously showed Sox9 expression in epithelium reconstituted from squamous esophageal cells from a conditional Shh transgenic mouse (48) . This may suggest that Sox9 is a direct target of Shh in the adult mouse esophagus via autocrine signaling, rather than mesenchymal-to-epithelial paracrine signaling via Bmp4. Certainly, Sox9 is known to be a direct target of Shh signaling in mouse chondrocytes (44) . Alternatively, additional factors may be required, meaning that Bmp4 is still necessary, although not sufficient, for Shh-induced Sox9 expression and columnar differentiation.
In addition to driving formation of a columnar epithelium with expression of the columnar cell differentiation marker Ck8, Sox9 also promoted expression of A33, which is an intestinal epithelial-specific glycoprotein (18) , although its expression pattern was not distinctively membranous. A33 mRNA is strongly expressed in BE, weakly expressed in the stomach, and not expressed in the normal squamous esophagus (50) . We confirmed that A33 is specifically expressed in BE, but not normal human esophagus, at the protein level and, therefore, demonstrate that Sox9 is able to partially induce an intestinaltype phenotypic change in squamous esophageal epithelium that is seen in BE.
Previous studies demonstrated the expression of CDX2, a transcription factor known to be involved in intestinal differentiation, in BE (10, 14, 29) . This and the observation that transgenic expression of CDX2 induces intestinal metaplasia in gastric columnar epithelial cells (31, 37) suggest the possibility that CDX2 may drive intestinal differentiation if expressed in squamous esophageal cells. However, we did not observe an effect of CDX2 alone on the reconstitution of the squamous epithelium in our model. This is consistent with recent data from a transgenic mouse model with CDX2 expression under the control of the squamous epithelial-specific Ck14 promoter, which has a largely normal-appearing squamous epithelium without evidence of columnar differentiation (22) . We also investigated the possibility that ectopic coexpression of CDX2 with Sox9 might lead to further intestinalization of the predominantly simple columnar phenotype caused by Sox9 alone in our in vivo model. However, we did not observe expression of other intestinal proteins (villin and Muc2) in reconstituted epithelium where CDX2 and Sox9 were coexpressed. Our data do not rule out a role for CDX2 in the pathogenesis of BE, and it is likely that additional factors are required.
Our data provide compelling evidence to support a role for Sox9 in the pathogenesis of BE. Together with our previous findings (48) , the data presented here provide further evidence for the importance of Shh signaling in this disease. We propose that Shh-induced expression of Sox9 may represent one of the earliest changes in the development of columnar metaplasia in the esophagus. Consistent with our previous work (48), a recent study also reported evidence of Shh signaling in BE as well as EAC (51) . Intriguingly, growth of the EAC cell line OE33 is inhibited by blocking Shh signaling in vitro (1) . These data raise the possibility that the Shh pathway may be a potential therapeutic target for the treatment of BE and/or EAC. Given that inhibitors of the Shh signaling pathway are in clinical trials for other conditions, this approach could potentially be tested in the near future.
